Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | FASN | P49327 | 5/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 11/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104 | 0.87 | BRD4 (0.59) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL10103 | 0.87 | BRD4 (0.59) | BRD4BRD2EP300BRD3BRDT | |
| SCHEMBL22220911 | 0.87 | FASN (0.53) | ALDH1A1CYP1A2GAACYP2C9CYP2C19 | |
| SCHEMBL10379581 | 0.87 | FASN (0.53) | ALDH1A1CYP1A2GAACYP2C9CYP2C19 | |
| SCHEMBL10378718 | 0.84 | FASN (0.67) | FASNABCC1BRD4 | |
| SCHEMBL22220779 | 0.84 | FASN (0.67) | FASNABCC1BRD4 | |
| SCHEMBL22220780 | 0.84 | FASN (0.60) | FASNBRD4 | |
| SCHEMBL22220935 | 0.84 | FASN (0.75) | FASNABCC1BRD4 | |
| SCHEMBL10378579 | 0.84 | FASN (0.75) | FASNABCC1BRD4 | |
| SCHEMBL10379907 | 0.84 | FASN (0.60) | FASNBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-11-14 | — | — | US | disclosed |
| WO-2012096928-A2 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303551-A1 | PYRIMIDINONE DERIVATIVES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FPGS, DHPS | ALDH1A1 349/4885CYP1A2 560/4885GAA 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.